As for the potential non-radiographic disease nod, AbbVie is leveraging data from Select-Axis 2, where Rinvoq hit its primary endpoints, as well as "most ranked secondary endpoints," AbbVie said in a release. Once-daily treatment with Rinvoq 15mg curbed signs and symptoms of the disorder, including back pain and inflammation, AbbVie said. The drug also charted improvements in physical function and disease activity at the 14-week mark versus placebo, the drugmaker added. Safety across patients in these trials was "generally consistent" with Rinvoq's established profile, and no new safety risks cropped up. That's good news, given the recent safety concerns plaguing the JAK inhibitor class at large. In September, the FDA added a classwide boxed warning to Rinvoq's label to include information about increased risks of serious heart-related events, cancer, blood clots and death.